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Sapproximately 50% of patients with discrete masses will be
found to have normal thymic pathologic conditions and so
will have undergone what might be termed an unnecessary
procedure. The presence or absence of symptoms was not
found to be useful in selecting patients with discrete thymic
masses requiring an intervention as it appears to be in pa-
tients with diffusely enlarged thymus glands.
With regard to a role for functional imaging, the available
evidence suggests that positron emission tomographic scan-
ning has only marginal utility in differentiating benign from
malignant processes within the thymus.21,22 At our insti-
tutions, we do not employ positron emission tomographic
scans to aid in the differential diagnosis of enlarged
thymus glands unless there is a history of or clinical
suspicion of lymphoma, which is generally markedly
fluorodeoxyglucose-avid. Future refinements in nuclear tu-
mor imaging or other radiologic techniques that may help to
delineate processes that should/should not be resected
would represent major advances in this field.
Although this study is obviously limited by its retrospec-
tive nature and its modest sample size, we believe that the
perfect correlation that we have found between an asymp-
tomatic presentation and the discovery of benign pathologic
conditions in diffusely enlarged thymus glands is suffi-
ciently impressive to guide management decisions. We rec-
ommend that patients with diffusely enlarged thymus
glands and no symptoms referable to the thymus undergo
observation with serial CT scanning while those with symp-
toms undergo thymic biopsy.
We thank Makoto Katsumata, PhD, for his contribution to sta-
tistical analyses.References
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DrMichaelWeyant (Aurora, Colo). I thank the authors for pro-
viding me with the manuscript and slides well ahead of the dead-
line. I enjoyed the paper very much.
Dr Singla, you and your colleagues have been able to address
a clinical scenario that is frequently encountered by thoracic sur-
geons. Until now, we have had no concrete recommendations
about how to deal with the problem. I think your series represents
the largest published to date regarding this phenomenon. The most
interesting aspect of your presentation deals with the diffusely en-
larged thymus, and I have a few questions.
Your data state that 4 of the 36 patients who had resection of
a diffusely enlarged thymus had abnormal pathologic features,
and they were lymphomas in all 4 of the cases. Inasmuch as 4 of
the patients were symptomatic and in half the patients who had
no symptoms no abnormal pathologic condition was demon-
strated, you recommend that if a patient has no symptoms and a dif-
fusely enlarged thymus, he or she can be monitored without
resection. I would like to play the devil’s advocate: Most of us
find it very difficult to attribute the true symptoms of the patient
to the thymus; the symptoms are very nonspecific and unreliable.
Therefore, you could use that as one of the limitations of your
study in gauging whether the patient’s symptoms are truly attribut-
able to the thymus. In that setting, if you look at the other side of
the argument, you would say that in 4 of these 36 patients who
have a diffusely enlarged thymus, greater than 10% of the time
you find abnormal pathologic features. You actually may be able
to submit an opposite conclusion—maybe resection should berdiovascular Surgery c Volume 140, Number 5 981
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are so unreliable. May I have your comments on that?
Dr Singla. You are correct that 4 of the patients with diffusely
enlarged thymus glands and symptoms actually had lymphoma,
and our recommendation is that for patients with lymphoma bi-
opsy is probably preferable (since it is less morbid) to resection.
In most instances, a CT-guided core needle biopsy will be suffi-
cient, but if more tissue is needed a Chamberlain procedure can
be done. Having said this, for the rest of the patients—those who
clearly have no symptoms—our recommendation is to wait and
watch. One could wait for 3 to 6 months and then scan them again
with little risk of missing anything. It is unlikely that even thy-
moma will become metastatic in 3 to 6 months. If the first scan
is unchanged, one could then do a scan yearly after that for about
5 years. Our data support the theory that nearly all of those patients
will never need surgery.
I think that one should have a low threshold to biopsy if any
symptoms are present that can be related in any way to the thymus.
This would include any lymphoma-type symptoms (for example,
‘‘B’’ symptoms) or symptoms that can result from compression
of structures around the thymus (such as cough or chest pain).
Dr Weyant.My second comment relating to your biopsy point
is that it might be wiser to resect the thymus rather that doing a bi-
opsy in these patients because of the amount of tissue required and
the fact that it is quite difficult to get adequate biopsy tissue. All of
the abnormal pathologic features you have demonstrated were
lymphoma.
Dr Singla. I shall ask Dr Shrager, my senior surgeon, to respond
because he has more experience doing these operations. Let me
ask him for some comments.
Dr Shrager. If you can do a transcervical thymectomy—if you
know how to do that—then maybe it is not unreasonable to do
a thymectomy in the case of a symptomatic gland, because it prob-
ably is just as benign a procedure as doing a Chamberlain proce-
dure. If you have pathologists who are comfortable, with good
flow cytometry, in making a diagnosis of lymphoma on the basis
of a needle biopsy, then a core needle would probably be the
way to go in one of these symptomatic glands.
DrWeyant. In looking at the patients in whom you re-reviewed
the pathologic features for thymic hyperplasia, you found that in
all except 3 the diagnosis was refuted and changed after re-review.
What is the reasoning behind that? Why do you think after the re-
review the diagnosis was actually changed?
Dr Singla. That is a very good question. In discussing thymic
hyperplasia, a lot of pathologists who do not have in-depth expe-
rience with thymic diseases will call any gland with increase in
the weight or the size of the gland ‘‘hyperplastic.’’ On the first
time around in pathology, when a pathologist other than our key
thymic pathologist often reviewed the cases, the thymuses that
were enlarged but did not actually demonstrate histologic follicu-
lar hyperplasia were often classified as ‘‘thymic hyperplasia.’’
When we went back, we actually went more in depth into the his-
tologic characteristics and found that most of those patients did not
demonstrate true histologic thymic follicular hyperplasia. There is
a difference between follicular hyperplasia (which is a histologic
finding) and simple enlargement of the gland. It is actually the fol-
licular hyperplasia that has been closely associated with autoim-
mune diseases, and that was one of the reasons that we went982 The Journal of Thoracic and Cardiovascular Surgback to see whether these thymic hyperplasias were actual exam-
ples of follicular hyperplasia or not.
Dr Robert Cerfolio (Birmingham, Ala).Are you sure you stud-
ied the right patients, or should you have studied patients like the
45 or 50 I have in my practice that I have not operated on and fol-
low up every year with a CT scan?
Dr Singla. I think we did our best to study these patients in de-
tail. We did go into depth in reading all the notes and talking with
these patients.
Dr Cerfolio. Did you study any of the patients who did not get
operated on?
Dr Singla. No, sir. These patients were all patients who had
been operated on.
Dr Cerfolio. Are you sure you studied the right patients or
should you go back and look at patients with enlarged glands
who have been followed up and have never undergone surgical re-
section and see how they did?
Dr Singla. That is a very good suggestion.We can do that, but at
present in the current data I only have patients that were operated
on.
Dr Cerfolio. I do not think that any new technology that makes
an operation less minimally invasive or easier to do or to recover
from should change the indication for surgery. For example, I
am doing lots of robotic thymectomies now. They are fun and
the patients go home the next day. You had mentioned that the
fact that you can do these from the neck might influence your in-
dication. Do you think that is true or should it be the patient’s anx-
iety that influences your decision, or the anatomic features of the
gland itself, and not the surgical approach?
Dr Singla. Dr Cerfolio, I did not say that doing transcervical
thymectomy should influence our indications. I said that in the
past it may have influenced our decision before we knew that it
was safe to leave many of these untouched. With the results of
this study, I think we can now see that many of the patients in
whom we performed thymectomy, partly because of the availabil-
ity of this simple approach, could safely have been left without sur-
gical intervention.
However, patients do have anxiety, especially when they have
been referred and told that they have a mass. Anybody in this au-
diencewhowas told that he or she had a mass would want answers,
so a lot does have to do with patient anxiety. In the scenario that
you have stated, that you have more advanced technology, yes,
we can definitely go in and operate on these patients safely. At
the same time, if we do not need to operate on these patients,
then we should not.
DrCerfolio.You sound like a great politician, so let me try to pin
down your position. Does the fact that you can do an operation min-
imally invasively change your indication for surgery: yes or no?
Dr Singla. I would prefer to ask Dr Shrager to answer that ques-
tion, but I would say no.
Dr Frederic Grannis (Duarte, Calif). Thank you for doing this
study. It gives very good information on a common problem. We
know from the data from the leukocytapheresis (LCAP) study that
if you use a CT scan to screen people for lung cancer, you find at
least 3 thymic enlargements in 1000 patients, maybe more. Thus,
this is a common problem that we need to learn how to manage.
I want to ask you 2 specific questions. First, did you do positron
emission tomographic scans on any of these patients? Doesery c November 2010
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a nonthymoma?
Second, recently we avoided surgery in a patient with diffuse
mass in the thymus because of hyperthyroidism. After that
patient was treated for hyperthyroidism, the thymic hyperplasia
resolved.
Dr Singla. Thank you, sir. With regard to your first question,
there have been some small studies using positron emission
tomographic scans in trying to read thymomas and other thymic
disorders. Some of these studies have suggested that such scans
can be useful. After discussing this with my colleagues and senior
colleagues, we believe that the data are not robust enough to say
that the positron emission tomographic scan alone would be suffi-
cient to give us the correct indication or correct information.
I think it is a combination of what we are suggesting is a combina-The Journal of Thoracic and Cation; a combination of signs and symptoms along with the CT scan
would be more appropriate at this stage in helping make the deci-
sion on how to proceed. In the coming years, with more informa-
tion coming, I think the positron emission tomographic scan may
add a lot of information. A negative positron emission tomo-
graphic scan would certainly be reassuring in patients on whom
you decide to follow up rather than operate.
Second, as you mentioned with the thyroid disorders, there are
clearly several diseases that are widely known to cause thymic
enlargement, and being aware of these is an important way to avoid
unnecessary thymectomy. Besides Graves disease, another com-
mon one is postchemotherapy rebound enlargement of the thymus.
I am not sure whether these represent actual follicular hyperplasia
or just enlargement, but they generally resolve with time or with
resolution of the underlying problem (eg, hyperthyroidism).rdiovascular Surgery c Volume 140, Number 5 983
